inclusion criteria: * participants must be at high-risk for coronavirus disease 2019 (covid-19) disease progression by fulfilling at least one of the following criteria at screening: * presence of chronic pulmonary disease, chronic obstructive pulmonary disease (copd), pulmonary hypertension * diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment * hypertension, requiring at least one oral medication for treatment * immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cluster of differentiation 4 \[cd4\] t-cell count of \<200 per cubic millimeter \[mm\^3\]) * immunocompromised status due to medication (e.g., taking 20 milligram \[mg\] or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, cancer therapies) * any chronic disease that is associated with high risk for severe covid in the opinion of the site investigator * body mass index ≥35 kilogram per square meter (kg/m\^2) (based on self-reported weight and height). * documented severe acute respiratory syndrome coronavirus 2 positive diagnostic test of ≤7 days at the time of screening * symptomatic for covid-19 for ≤72 hours at the time of screening (defined as having at least 2 of the following symptoms of covid-19 that is of new onset or has worsened from baseline, and include fever, chills, myalgia, arthralgia, headache, fatigue, cough, sore throat, nasal congestion, anosmia, ageusia, nausea, vomiting, or diarrhea. if only two symptoms are present, they cannot both be anosmia and ageusia) * capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the inform consent form and in this protocol * agree to participate in all remote, in-person or home visits as required in the protocol and provide updated contact information as necessary. * female of childbearing potential must agree to practice adequate contraception during the study

inclusion criteria: * participants must be at high-risk for coronavirus disease 2019 (covid-19) disease progression by fulfilling at least one of the following criteria at screening: * presence of chronic pulmonary disease, chronic obstructive pulmonary disease (copd), pulmonary hypertension * diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment * hypertension, requiring at least one oral medication for treatment * immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cluster of differentiation 4 \[cd4\] t-cell count of \<200 per cubic millimeter \[mm\^3\]) * immunocompromised status due to medication (e.g., taking 20 milligram \[mg\] or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, cancer therapies) * any chronic disease that is associated with high risk for severe covid in the opinion of the site investigator * body mass index ≥35 kilogram per square meter (kg/m\^2) (based on self-reported weight and height). * documented severe acute respiratory syndrome coronavirus 2 positive diagnostic test of ≤7 days at the time of screening * symptomatic for covid-19 for ≤72 hours at the time of screening (defined as having at least 2 of the following symptoms of covid-19 that is of new onset or has worsened from baseline, and include fever, chills, myalgia, arthralgia, headache, fatigue, cough, sore throat, nasal congestion, anosmia, ageusia, nausea, vomiting, or diarrhea. if only two symptoms are present, they cannot both be anosmia and ageusia) * capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the inform consent form and in this protocol * agree to participate in all remote, in-person or home visits as required in the protocol and provide updated contact information as necessary. * female of childbearing potential must agree to practice adequate contraception during the study

inclusion criteria: - participants must be at high-risk for coronavirus disease 2019 (covid-19) disease progression by fulfilling at least one of the following criteria at screening: - presence of chronic pulmonary disease, chronic obstructive pulmonary disease (copd), pulmonary hypertension - diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment - hypertension, requiring at least one oral medication for treatment - immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cluster of differentiation 4 [cd4] t-cell count of <200 per cubic millimeter [mm^3]) - immunocompromised status due to medication (e.g., taking 20 milligram [mg] or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, cancer therapies) - any chronic disease that is associated with high risk for severe covid in the opinion of the site investigator - body mass index ≥35 kilogram per square meter (kg/m^2) (based on self-reported weight and height). - documented severe acute respiratory syndrome coronavirus 2 positive diagnostic test of ≤7 days at the time of screening - symptomatic for covid-19 for ≤72 hours at the time of screening (defined as having at least 2 of the following symptoms of covid-19 that is of new onset or has worsened from baseline, and include fever, chills, myalgia, arthralgia, headache, fatigue, cough, sore throat, nasal congestion, anosmia, ageusia, nausea, vomiting, or diarrhea. if only two symptoms are present, they cannot both be anosmia and ageusia) - capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the inform consent form and in this protocol - agree to participate in all remote, in-person or home visits as required in the protocol and provide updated contact information as necessary. - female of childbearing potential must agree to practice adequate contraception during the study

inclusion criteria: - participants must be at high-risk for coronavirus disease 2019 (covid-19) disease progression by fulfilling at least one of the following criteria at screening: - presence of chronic pulmonary disease, chronic obstructive pulmonary disease (copd), pulmonary hypertension - diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for treatment - hypertension, requiring at least one oral medication for treatment - immunocompromised status due to disease (e.g., those living with human immunodeficiency virus with a cluster of differentiation 4 [cd4] t-cell count of <200 per cubic millimeter [mm^3]) - immunocompromised status due to medication (e.g., taking 20 milligram [mg] or more of prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, cancer therapies) - any chronic disease that is associated with high risk for severe covid in the opinion of the site investigator - body mass index ≥35 kilogram per square meter (kg/m^2) (based on self-reported weight and height). - documented severe acute respiratory syndrome coronavirus 2 positive diagnostic test of ≤7 days at the time of screening - symptomatic for covid-19 for ≤72 hours at the time of screening (defined as having at least 2 of the following symptoms of covid-19 that is of new onset or has worsened from baseline, and include fever, chills, myalgia, arthralgia, headache, fatigue, cough, sore throat, nasal congestion, anosmia, ageusia, nausea, vomiting, or diarrhea. if only two symptoms are present, they cannot both be anosmia and ageusia) - capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the inform consent form and in this protocol - agree to participate in all remote, in-person or home visits as required in the protocol and provide updated contact information as necessary. - female of childbearing potential must agree to practice adequate contraception during the study